Literature DB >> 30015589

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Robert Zivadinov1, Eleonora Tavazzi1, Niels Bergsland1, Jesper Hagemeier1, Fuchun Lin1, Michael G Dwyer1, Ellen Carl1, Channa Kolb1, David Hojnacki1, Deepa Ramasamy1, Jacqueline Durfee1, Bianca Weinstock-Guttman1, Ferdinand Schweser1.   

Abstract

Purpose To study deep gray matter susceptibility in multiple sclerosis (MS) by using quantitative susceptibility mapping (QSM) and to assess the relationship between susceptibility and clinical disability. Materials and Methods For this prospective study between March 2009 and November 2013, 600 participants with MS (452 with relapsing-remitting MS and 148 with secondary progressive MS) and 250 age- and sex-matched healthy control participants were imaged with 3.0-T MRI to measure magnetic susceptibility. Deep gray matter susceptibility (in parts per billion) was analyzed by using region of interest and voxelwise methods. QSM and MRI volumetric differences between study groups and associations with clinical outcomes were assessed. Analysis of covariance, multivariable linear regression, and voxelwise analyses, controlling for age and sex, were used to compare study groups and to explore associations between MRI and clinical outcomes. Results Compared with control participants, participants with MS presented with lower thalamic susceptibility (-7.5 ppb vs -1.1 ppb; P < .001) and higher susceptibility of basal ganglia (62 ppb vs 54.8 ppb; P < .001). Lower thalamic susceptibility was associated with longer disease duration (β = -0.42; P = .002), higher degree of disability (β = -0.64; P = .03), and secondary-progressive course (β = -4.3; P = .009). Higher susceptibility of the globus pallidus was associated with higher disability (β = 2; P = .03). After correcting for each individual structural volume in voxelwise analysis, lower thalamic susceptibility and higher susceptibility of the globus pallidus remained associated with clinical disability (P < .05). Conclusion Quantitative susceptibility mapping (QSM) suggests that altered deep gray matter iron is associated with the evolution of multiple sclerosis (MS) and on disability accrual, independent of tissue atrophy. © RSNA, 2018 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30015589      PMCID: PMC6219694          DOI: 10.1148/radiol.2018180136

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  40 in total

1.  Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference.

Authors:  Stephen M Smith; Thomas E Nichols
Journal:  Neuroimage       Date:  2008-04-11       Impact factor: 6.556

2.  Subcortical gray matter segmentation and voxel-based analysis using transverse relaxation and quantitative susceptibility mapping with application to multiple sclerosis.

Authors:  Dana Cobzas; Hongfu Sun; Andrew J Walsh; R Marc Lebel; Gregg Blevins; Alan H Wilman
Journal:  J Magn Reson Imaging       Date:  2015-05-18       Impact factor: 4.813

3.  Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome.

Authors:  Ali M Al-Radaideh; Samuel J Wharton; Su-Yin Lim; Christopher R Tench; Paul S Morgan; Richard W Bowtell; Cris S Constantinescu; Penny A Gowland
Journal:  Mult Scler       Date:  2012-11-08       Impact factor: 6.312

Review 4.  Quantitative susceptibility mapping: current status and future directions.

Authors:  E Mark Haacke; Saifeng Liu; Sagar Buch; Weili Zheng; Dongmei Wu; Yongquan Ye
Journal:  Magn Reson Imaging       Date:  2014-10-25       Impact factor: 2.546

5.  Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls.

Authors:  C A Habib; M Liu; N Bawany; J Garbern; I Krumbein; H-J Mentzel; J Reichenbach; C Magnano; R Zivadinov; E M Haacke
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-24       Impact factor: 3.825

6.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Authors:  A Burgetova; P Dusek; M Vaneckova; D Horakova; C Langkammer; J Krasensky; L Sobisek; P Matras; M Masek; Z Seidl
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

7.  Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases.

Authors:  Kathryn E Hammond; Janine M Lupo; Duan Xu; Meredith Metcalf; Douglas A C Kelley; Daniel Pelletier; Susan M Chang; Pratik Mukherjee; Daniel B Vigneron; Sarah J Nelson
Journal:  Neuroimage       Date:  2007-11-07       Impact factor: 6.556

8.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

9.  Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.

Authors:  Veela Mehta; Wei Pei; Grant Yang; Suyang Li; Eashwar Swamy; Aaron Boster; Petra Schmalbrock; David Pitt
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron.

Authors:  Lukas Haider; Constantina Simeonidou; Günther Steinberger; Simon Hametner; Nikolaos Grigoriadis; Georgia Deretzi; Gabor G Kovacs; Alexandra Kutzelnigg; Hans Lassmann; Josa M Frischer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-06-04       Impact factor: 10.154

View more
  25 in total

1.  Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study.

Authors:  G Pontillo; S Cocozza; R Lanzillo; C Russo; M D Stasi; C Paolella; E A Vola; C Criscuolo; P Borrelli; G Palma; E Tedeschi; V B Morra; A Elefante; A Brunetti
Journal:  AJNR Am J Neuroradiol       Date:  2018-12-20       Impact factor: 3.825

2.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

Review 3.  The Relevance of Neuroimaging Findings to Physical Disability in Multiple Sclerosis.

Authors:  Rahşan Göçmen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

4.  Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Authors:  Yanis Taege; Jesper Hagemeier; Niels Bergsland; Michael G Dwyer; Bianca Weinstock-Guttman; Robert Zivadinov; Ferdinand Schweser
Journal:  Neuroimage       Date:  2018-11-14       Impact factor: 6.556

5.  Lack of association between C282Y and H63D polymorphisms in the hemochromatosis gene and risk of multiple sclerosis: A meta-analysis.

Authors:  Nada Starčević Čizmarević; Božena Ćurko-Cofek; Vesna Barac-Latas; Borut Peterlin; Smiljana Ristić
Journal:  Biomed Rep       Date:  2021-12-17

6.  Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome.

Authors:  Ali I Mirza; Feng Zhu; Natalie Knox; Jessica D Forbes; Gary Van Domselaar; Charles N Bernstein; Morag Graham; Ruth Ann Marrie; Janace Hart; E Ann Yeh; Douglas L Arnold; Amit Bar-Or; Julia O'Mahony; Yinshan Zhao; William Hsiao; Brenda Banwell; Emmanuelle Waubant; Helen Tremlett
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

Review 7.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

8.  Impact of trial design and patient heterogeneity on the identification of clinically effective therapies for progressive MS.

Authors:  Elizabeth A Mills; Joel A Begay; Caitlyn Fisher; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

9.  Unraveling Deep Gray Matter Atrophy and Iron and Myelin Changes in Multiple Sclerosis.

Authors:  G Pontillo; M Petracca; S Monti; M Quarantelli; C Criscuolo; R Lanzillo; E Tedeschi; A Elefante; V Brescia Morra; A Brunetti; S Cocozza; G Palma
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-22       Impact factor: 4.966

10.  Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Authors:  Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki
Journal:  Neurology       Date:  2019-07-08       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.